Rapid and accurate antibody testing on a large scale is key to address the challenges of the COVID-19 pandemic. Over time, SARS-CoV-2 IgG antibodies remain the primary antibodies present.
The Siemens Healthineers SARS-CoV-2 IgG (COV2G) Assay* is the first FDA EUA-authorized semi-quantitative assay to help clinicians assess the level of an individual‘s immune response over time.
“Being able to measure a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection may be useful as we continue to learn more about the virus and what the existence of antibodies may mean. There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but today’s authorizations give us additional tools to evaluate those antibodies as we continue to research and study this virus.”
Tim Stenzel, M.D., Ph.D., Director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health (read press release)
Results can be produced in as little as 16 minutes on the Dimension® and Dimension Vista® Systems† and 25 minutes on the Atellica® IM Analyzer with a capacity to process up to 440 assays per hour§ along with the sensitivity and specificity laboratories have come to expect from us.
ADVIA Centaur® XP/XPT
Interested in Frequently Asked Questions (FAQs) for SARS-CoV-2 Antibody testing!
Please fill out the form below to receive Frequently Asked Questions (FAQs) for SARS-CoV-2 Antibody testing.
Siemens Healthineers offers a robust portfolio of reliable antibody tests to support patient care
We offer both the SARS-CoV-2 IgG antibody assay and the SARS-CoV-2 Total antibody assay. The combination of these assays provides a complete picture of a patient’s serological status for the most accurate results throughout his or her continuum of care.
SARS-CoV-2 IgG (COV2G) Qualitative and Semi-quantitative Assay
The COV2G assay is a qualitative and semi-quantitative SARS-CoV-2 antibody assay that enables clinicians to detect the level of IgG antibodies in a patient’s blood sample and assess relative changes over time. The assay is more appropriate for later seroconversion. With this numerical value, clinicians will have a baseline and be better equipped to track the long-term duration of an individual’s immune response. Comparison of numerical results will help determine how the immune response develops in an individual and persists over time.
SARS-CoV-2 Total (COV2T) Assay*
The COV2T assay detects both IgM and longer-lasting IgG antibodies with 100% sensitivity‡ and 99.8% specificity for recent and prior infection. Total antibody assays can be used as an adjunct to PCR tests to identify a patient’s immune response during early infection and aid in clinical assessment.1,2